Danaher Q1 2026 Earnings Update

Danaher had another somewhat uneventful quarter. Margin in biotechnology segment improved YoY to reach 42.7% in 1Q'26. Life Sciences segment's core revenue grew at only 0.5% despite having an easy comp of -4% in 1Q'25.
Open original source